Until more recently, copy number variant detection in breast and ovarian cancer has been limited to studies of BRCA1 and BRCA2 genes using approaches such as MLPA, long-range and/or quantitative PCR in the primary screen, and the contribution of CNVs in other hereditary cancer predisposition genes was relatively unknown. The gene discussed is BRCA2; the disease is ovarian cancer.